摘要
乳腺癌已成为女性中最常见的癌症,也是全球女性癌症性相关死亡的第二大病因。HER2阳性乳腺癌的主要特征是HER2过表达,也被认为是第二具侵袭性的亚型。为了获得最大的抗肿瘤活性,使更多的HER2乳腺癌患者受益,研究者们将抗体和细胞毒性药物结合在一起形成抗体–药物偶联物。抗体–药物偶联物(ADC)正在彻底改变癌症治疗,增加了另一种重要的系统治疗新类别。ADC是一种特殊设计的治疗方法,它通过定向的抗体药物传递和释放细胞毒性化疗有效载荷来靶向表达特定癌症抗原的细胞。本文将重点介绍几种用于乳腺癌治疗的ADC的研究进展,并讨论它们所带来的机遇和挑战。
Breast cancer has become the most common cancer among women and the second leading cause of cancer-related deaths among women worldwide. HER2-positive breast cancer is characterized pri-marily by HER2 overexpression, which is also considered to be the second most aggressive subtype. To achieve maximum antitumor activity and benefit more HER2 breast cancer patients, the re-searchers combined the antibody with the cytotoxic drug to form an antibody-drug conjugate. An-tibody-drug conjugate (ADC) are revolutionizing cancer therapy, adding another important new class of systemic therapies. ADC is a specially designed therapy that targets cells expressing specific cancer antigens through targeted antibody drug delivery and the release of cytotoxic chemotherapy payloads. This article will highlight the research advances in several ADCs for the treatment of breast cancer and discuss the opportunities and challenges they present.
出处
《临床医学进展》
2024年第1期1801-1807,共7页
Advances in Clinical Medicine
